semgine GmbH - Product release of the semgine sciPlorer® 1.3

Berlin software enterprise semgine GmbH has completed the new release of its semgine sciPlorer®. semgine sciPlorer® is the first product based on the semgine® semantic search technology and the first semantic information retrieval assistant specially developed for researchers working in the field of drugs discovery and biomedical science.

Version 1.3 of the semgine sciPlorer® enables scientists to have terms explained to them simply using brief, concise collections of facts. At the same time, the results filtering has been fundamentally expanded, so more and better results can now be achieved.

"The reports now available, with their brief, clear facts, allow for very fast and effortless information acquisition and are a clear unique selling proposition for the semgine sciPlorer®" explains Dr Martin C. Hirsch, CEO of semgine GmbH. "With the extraction of facts from the Internet, we are consistently expanding the semgine sciPlorer®, developing it into a semantic search engine for the biomedical sciences. We’ve brought Web 3.0 a step closer for the biomedical sciences."

The semgine sciPlorer® is based on a completely new approach, which applies the principles of cognitive neuroscience to information processing. While conventional search engines create a normal word-based, full-text index of documents, semgine® builds up a semantic index, enabling users to accurately pinpoint individual facts in documents.

"We've really 'hit a nerve' in the community with the semgine sciPlorer®" notes Dr Thomas Meyer, Sales Manager Life Sciences at semgine GmbH. "A test customer summed it up aptly: With the semgine sciPlorer® you've developed an excellent information retrieval solution with a technically perfected refinement strategy."

About semgine GmbH
semgine GmbH (www.semgine.com) develops software frameworks for building semantic knowledge assistants for the Web 3.0. Its unique approach, utilising Brainlike Information Management, is derived from current insights into cognitive neurosciences, forming the basis for cutting-edge software technology designed to retrieve complex information relationships quickly and accurately.

The company was founded in 1994 by Dr Martin C. Hirsch, neurobiologist and grandson of physicist and Nobel Laureate Werner Heisenberg. semgine GmbH focuses on the life sciences sector and its customers include Altana Pharma AG, BBraun AG, Honda Research Institute Europe and Sanofi-Aventis Deutschland GmbH. The core technology is funded by the German Ministry of Education and Research and, within the BioSim project, by the 6th Framework Programme of the European Commission.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...